Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA.
Gastroenterology. 2013 Mar;144(3):512-27. doi: 10.1053/j.gastro.2013.01.002. Epub 2013 Jan 9.
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third greatest cause of cancer-related death worldwide, and its incidence is increasing. Despite the significant improvement in management of HCC over the past 30 years, there are no effective chemoprevention strategies, and only one systemic therapy has been approved for patients with advanced tumors. This drug, sorafenib, acts on tumor cells and the stroma. HCC develops from chronically damaged tissue that contains large amounts of inflammation and fibrosis, which also promote tumor progression and resistance to therapy. Increasing our understanding of how stromal components interact with cancer cells and the signaling pathways involved could help identify new therapeutic and chemopreventive targets.
肝细胞癌（HCC）是最常见的原发性肝脏肿瘤，也是全球癌症相关死亡的第三大原因，其发病率正在上升。尽管在过去 30 年中 HCC 的治疗管理取得了显著进展，但仍没有有效的化学预防策略，仅有一种系统疗法被批准用于晚期肿瘤患者。这种药物索拉非尼作用于肿瘤细胞及其基质。HCC 由慢性受损组织发展而来，其中含有大量炎症和纤维化，这也促进了肿瘤的进展和对治疗的耐药性。加深我们对基质成分与癌细胞相互作用以及涉及的信号通路的理解，可能有助于确定新的治疗和化学预防靶点。
